Eric Furfine
52Patents
18h-index
81Co-inventors
87Inventor score
Filing activity: Mar 28, 1996 → Oct 23, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8092803B2 | VEGF antagonist formulations for intravitreal administration | Chemistry; Metallurgy | 103 | Active |
| US7608261B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 87 | Active |
| US8221765B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 63 | Active |
| US7807164B2 | Lyophilized VEGF antagonist formulations for intravitreal administration | Chemistry; Metallurgy | 60 | Active |
| US10464992B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 59 | Active |
| US9340594B2 | VEGF antagonist formulations for intravitreal administration | Chemistry; Metallurgy | 56 | Active |
| US8481046B2 | VEGF antagonist formulations for intravitreal administration | Chemistry; Metallurgy | 55 | Active |
| US9580489B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 49 | Active |
| US8802107B2 | VEGF antagonist formulations for intravitreal administration | Chemistry; Metallurgy | 48 | Active |
| US9914763B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 41 | Active |
| US8969289B2 | Serum albumin binding molecules | Chemistry; Metallurgy | 40 | Active |
| US10400025B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 40 | Active |
| US8728483B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 36 | Active |
| US6319946A | Inhibitors of aspartyl protease | Chemistry; Metallurgy | 35 | Expired |
| US6811780B2 | Methods of using cytokine antagonists to treat HIV infection and AIDS | Human Necessities | 32 | Expired |
| US7531172B2 | Methods of treating diseases with a VEGF antagonist | Human Necessities | 28 | Active |
| US9902762B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 27 | Active |
| US9540424B2 | Serum albumin binding molecules | Chemistry; Metallurgy | 26 | Active |
| US11084865B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 13 | Active |
| US11066458B2 | VEGF antagonist formulations suitable for intravitreal administration | Chemistry; Metallurgy | 12 | Active |
| US10221438B2 | Serum albumin binding molecules | Chemistry; Metallurgy | 10 | Active |
| US6559137B1 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | Chemistry; Metallurgy | 8 | Expired |
| US8388963B2 | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof | Human Necessities | 7 | Active |
| US6613743B2 | Sulfonamide inhibitors of aspartyl protease | Chemistry; Metallurgy | 6 | Expired |
| US9951130B2 | IL-6 antagonists and uses thereof | Chemistry; Metallurgy | 4 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.